Konakion Mm

Phytomenadione, the active ingredient in Konakion Mm, is a vitamin K presented as a hemostatic preparation for intramuscular, intravenous, and oral use. It is employed to correct vitamin K deficiency, prevent bleeding in newborns, and reverse anticoagulant over‑dosage.

GNH USA supplies Konakion Mm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Konakion Mm, a vitamin K agent, is used to manage disorders of coagulation by supplying the essential cofactor for clotting factor activation.

Vitamin K deficiency: restores normal clotting factor activity in patients with insufficient vitamin K levels, reducing bleeding risk. Prevention of hemorrhage in newborns: administered shortly after birth to newborns to prevent vitamin K‑deficiency bleeding. Reversal of anticoagulant (warfarin) over‑dosage: provides rapid replenishment of vitamin K to counteract excessive anticoagulation and normalize INR.

Phytomenadione may be associated with several adverse reactions, ranging from mild to severe.

Common Side Effects: - Injection site pain or erythema - Mild fever - Nausea or vomiting - Headache or dizziness

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction - Thrombosis or embolic events - Hemolytic anemia

Before using Konakion Mm, several precautionary measures should be considered to ensure safe administration.

Assess bleeding risk: evaluate patient’s coagulation status and recent anticoagulant use. Monitor for hypersensitivity: observe for signs of allergic reaction during and after administration. Use with caution in liver disease: impaired synthesis of clotting factors may alter response. Avoid in newborns with contraindications: follow neonatal dosing guidelines. Store at below 25°C: keep in the original pack, protect from moisture.

Phytomenadione can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Warfarin and other vitamin K antagonists: may diminish anticoagulant effect and increase clotting risk. - High‑dose vitamin K supplements: may counteract therapeutic action of Konakion Mm.

Moderate Interactions (Monitor Closely): - Broad‑spectrum antibiotics (e.g., cephalosporins): may alter gut flora and affect vitamin K levels, requiring monitoring. - Lipid‑lowering agents such as cholestyramine: can bind vitamin K and reduce its absorption. - Oral contraceptives: may increase vitamin K activity, necessitating periodic coagulation assessment.